Mounjaro 2.5mg: What the Starting Dose Is For and What to Expect

What the licensed guidance actually says about starting at 2.5mg

The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, specifies 2.5mg once weekly as the mandatory initiation dose for all patients, regardless of their starting weight or the maintenance dose they are working towards. The rationale is pharmacological: tirzepatide slows gastric emptying and suppresses appetite through dual receptor activity, and introducing that effect gradually reduces the likelihood of early nausea, vomiting and other gastrointestinal symptoms that cause people to stop treatment prematurely.

After four weeks at 2.5mg, the prescriber typically increases the dose to 5mg. Subsequent steps (7.5mg, 10mg, 12.5mg, up to 15mg) follow at roughly four-week intervals, based on tolerability and clinical response. The prescriber decides the pace; the schedule in the SmPC is a framework, not a guarantee. If you want to understand the practical mechanics of what comes inside a 2.5mg Mounjaro pen, that detail is covered separately.

NICE's appraisal of tirzepatide (TA1026) evaluated the medicine's effectiveness across the full licensed dose range; 2.5mg is not the dose that produced the trial results, but it is the dose that makes reaching those results tolerable for most people. Skipping or abbreviating it is not supported by the evidence base.

Why the SURMOUNT-1 results do not apply at 2.5mg, and what they do tell you

SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across the tirzepatide dose range over 72 weeks. At the 15mg maintenance dose, participants lost an average of around 20–21% of body weight. That figure is widely quoted. What it does not represent is the effect of staying at 2.5mg, participants spent only four weeks there before titration began.

The clinical significance of this is straightforward: if you feel little happening during your first month, that is expected and intended. The 2.5mg period is not a test of whether Mounjaro will work for you. Appetite suppression, blood-sugar regulation and weight reduction accumulate over months as the dose increases. Patients who interpret a quiet first month as treatment failure and stop are not giving the licensed regimen a fair trial.

Questions about measurement sometimes come up at this stage too, the volume in millilitres of a 2.5mg dose and how that converts to units are answered in detail if you need them, though for most people the pre-filled KwikPen removes any need to measure manually.

Side effects at 2.5mg: what tends to happen in the first four weeks

The most commonly reported side effects of tirzepatide are gastrointestinal: nausea, loose stools, constipation, indigestion, burping and occasional vomiting. The NHS medicines page for tirzepatide lists these clearly, noting they are typically most pronounced after starting or after a dose increase, and that they often settle within days to a couple of weeks.

At 2.5mg specifically, most people find these effects mild, which is precisely the point of the starter dose. Eating smaller portions, avoiding high-fat or very rich meals, staying hydrated and injecting on a consistent day each week all help. If symptoms are severe or persistent, that is a conversation for your prescriber, not a reason to adjust the dose yourself.

The pen itself is straightforward to use: it arrives by DPD in plain, unbranded packaging, and each device is pre-filled with four weekly doses at the 2.5mg strength. No drawing up, no measuring. Injection sites are the abdomen, thigh or upper arm; rotating between them reduces local irritation. Storage instructions are in the Patient Information Leaflet, always follow those rather than any general guidance, as the room-temperature window is time-limited.

Moving from 2.5mg to 5mg: the clinical decision and what comes next

The transition from 2.5mg to 5mg is the first real titration step, and it is where the therapeutic work of Mounjaro begins in earnest. At 5mg and above, appetite reduction becomes meaningfully noticeable for most people, and the weight-loss trajectory that the SURMOUNT trial results reflect starts to take shape.

Whether you move up at four weeks or hold longer depends on how well the 2.5mg dose was tolerated and the clinical judgement of your prescriber. A fuller explanation of that decision, including what evidence a prescriber looks for before increasing, is covered on the 2.5mg to 5mg transition page. The full Mounjaro overview sets the entire dose schedule and evidence base in context if you are earlier in the research process.

Cost is a practical question at every stage. Private tirzepatide pricing varies by dose and provider; the cost context page explains what legitimate treatment prices include and why the lowest advertised price is rarely the complete picture. At nume, one transparent fee covers the consultation, prescription, and free next-working-day delivery, no subscriptions, no repeat charges without a fresh clinical review. Speak to our prescribers to find out whether tirzepatide is clinically suitable for you.